When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Nymox Corp (NASDAQ: NYMX) has been developing NX-1207 for the treatment of benign prostatic hyperplasia (BPH) for the last 20 years. In 2014, two pivotal Phase III trials missed their primary endpoint. Instead of conducting another set of trials in consultation with the FDA and EMA, Nymox has pursued tangents for the last 5 years – reporting data from long-term extension studies (extremely unlikely to be accepted by FDA as adequate evidence of efficacy), and claiming that approval filings would be made in near future all while raising ~$35M through private placements.